CW Advisors LLC Has $10.16 Million Stock Position in DexCom, Inc. $DXCM

Key Points

• CW Advisors LLC reduced its holdings in DexCom, Inc. by 12.2%, selling 20,659 shares, and now owns 148,679 shares valued at approximately $10.16 million.
• DexCom's latest quarterly earnings exceeded estimates with an EPS of $0.48 and revenue of $1.16 billion, reflecting a 15.2% year-over-year growth in revenue.
• Research analysts have adjusted price targets for DexCom, with Citigroup setting a new target of $102, while the overall consensus rating is a Moderate Buy with an average target price of $99.90.

CW Advisors LLC lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 12.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 148,679 shares of the medical device company's stock after selling 20,659 shares during the quarter. CW Advisors LLC's holdings in DexCom were worth $10,156,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Golden State Wealth Management LLC boosted its position in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new position in DexCom during the 1st quarter valued at approximately $27,000. Optiver Holding B.V. acquired a new position in DexCom during the 4th quarter worth $33,000. Heck Capital Advisors LLC acquired a new position in DexCom during the 4th quarter worth $38,000. Finally, Alpine Bank Wealth Management acquired a new position in DexCom during the 1st quarter worth $40,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price target for the company. Truist Financial initiated coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Oppenheimer boosted their price target on DexCom from $95.00 to $102.00 and gave the stock an "outperform" rating in a research report on Thursday, July 31st. Mizuho boosted their price target on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Finally, Wall Street Zen lowered DexCom from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 10th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Price Performance

Shares of DexCom stock traded up $0.16 during trading on Tuesday, hitting $76.12. The stock had a trading volume of 4,833,048 shares, compared to its average volume of 3,885,263. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The firm has a market cap of $29.85 billion, a P/E ratio of 52.86, a PEG ratio of 1.72 and a beta of 1.43. The business has a fifty day moving average of $82.67 and a two-hundred day moving average of $79.68. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company's revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the sale, the director directly owned 33,411 shares of the company's stock, valued at $2,766,430.80. The trade was a 9.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 1,466 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $88.99, for a total value of $130,459.34. Following the sale, the executive vice president directly owned 106,689 shares in the company, valued at $9,494,254.11. This trade represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 15,722 shares of company stock valued at $1,306,131 over the last ninety days. 0.32% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.